Request a quote

Custom RNA & RNA-LNP Manufacturing Services

Discover uBriGene’s RNA-LNP manufacturing platform and proprietary microfluidic LNP formulation technology, designed to reduce costs and accelerate timelines for therapeutic developers.

Request a Quote

Robust RNA & RNA-LNP Production Service Platform

The efficacy and safety of RNA-based therapeutics and vaccines rely on manufacturing high-quality RNA and encapsulating into optimal lipid nanoparticles (LNP). uBriGene provides an end-to-end CMC solution to developers of RNA-based medicines.

RNA, RNA-LNP Service Highlights

Comprehensive RNA Services

mRNA, circRNA, saRNA, and sgRNA
From plasmid template construction to RNA-LNP formulation
Research grade RNA production to GMP RNA-LNP manufacturing & testing

Optimized Platform Processes

Optimized RNA templates for high quality, high yield production
mRNA purity: >95%
circRNA purity: ~90%
saRNA integrity: ~85%
Efficient encapsulation microfluidic technology, >90% encapsulation rate

Comprehensive Analytics

Encapsulation efficiency
CE based capping and polyA tail analytics
Particle size, density & polydispersity index determination

Regulatory Support

Expert advanced therapeutics IND-filing support
Provide custom regional regulatory support
DMF framework in-place

RNA-LNP Production Services

Service Description Timeline Price
mRNA mRNA Production Custom mRNA production service for preclinical applications, mg to grams quantity 2 weeks Please Inquire
mRNA-LNP Production mRNA production and LNP formulation service for preclinical applications 2 Weeks
circRNA circRNA production Custom circRNA production service for preclinical applications, mg to grams quantity 2 Weeks
circRNA-LNP production circRNA production and LNP formulation service for preclinical applications 2 Weeks
saRNA saRNA Production Custom saRNA production service for preclinical applications, mg to grams quantity 2 Weeks
saRNA-LNP Production saRNA production and LNP formulation service for preclinical applications 2 Weeks
sgRNA-IVT sgRNA Production Custom sgRNA in vitro transcription service for preclinical applications, mg to grams quantity 2 Weeks
sgRNA-LNP Production sgRNA production and LNP formulation service for preclinical applications 2 Weeks
GMP Services GMP RNA / RNA-LNP Manufacturing GMP RNA, RNA-LNP process development, tech transfer, manufacturing and testing Varies

Need Help with RNA, RNA-LNP Production?

With our high productive RNA manufacturing platform and RNA-LNP formulation technologies, we can accelerate your RNA therapeutic and vaccine programs.

Preclinical and GMP materials
Integrated services, from plasmids to RNA-LNP
Request Quote

RNA Manufacturing Workflow

uBrigene's custom mRNA synthesis and LNP formulation service workflow.

mRNA/saRNA manufacturing workflow diagram

Microfluidic Mixing of RNA and Lipids

RNA in aqueous solvent, and lipid components in ethanol are mixed at an optimal flow rate.

Tangential Flow Filtration (TFF)

Removal of residual solvents and concentration of RNA-LNP into desired buffer.

Sterile Filtration

Filtration of RNA-LNP through a 0.2um sterile filter.

Fill/Finish

Final fill into drug product vials under aseptic conditions.

RNA-LNP Formulation Workflow

uBriGene has developed a scalable, cost-effective and time-reducing RNA-LNP manufacturing process that is adaptable to various RNA modalities (mRNA, circRNA, saRNA, and sgRNA) and lipid chemistries.

Key steps of our microfluidic RNA-LNP encapsulation technology include high-speed mixing of lipids and RNA solution, tangential flow filtration (TFF) for buffer exchange and RNA-LNP concentration, followed by sterile filtration and final product fill/finish..

Ask the RNA-LNP Expert

RNA-LNP Production Validation Data

High Quality mRNA Produced Leads to Higher Gene Expression

Fluorescent microscopy image of eGFP being highly expressed in cells with uBriGene produced mRNA-LNP.

Fig. 1. eGFP is highly Expressed in Cells with uBriGene Produced mRNA-LNP

RNA-LNP Formulation Screening Studies

Fig. 2. RNA-LNP formulation screening studies. Eight different LNP formulations (horizontals) have been screened for high GFP expression in different cell lines. GFP mRNA was used for this LNP formulation study. A: Glial cell line, B: Neuronal cell line, C: Macrophage cell line, D: Spermatocyte cell line.

RNA-LNP delivery efficiency varies among different cell lines in different culture media.

Chart of RNA-LNP delivery efficiency results

Fig. 3. RNA-LNP formulation screening studies in eight different culture media. GFP mRNA-LNP was used for this study. Horizontals are eight different cell culture media. A: Glial cell line, B: Neuronal cell line, C: Macrophage cell line, D: Spermatocyte cell line.

What Are the Differences Between mRNA and circRNA?

mRNA
Circular RNA
Format
Linear Circular
5’ Capping, PolyA tailing?
Yes No
Expression mechanism
5' cap structure + Kozak translation initiation site
IRES
Intracellular stability
Lower (within a week), dependent on capping efficiency and the length of polyA tail
Higher (around two weeks), no need for 5’ cap and polyA structure
Coding sequence limitations
Long, dependent on the upper limit of in vitro transcription enzymes
Circularization efficiency decreases as the length increases
Production yield
High in vitro transcription yield
High in vitro transcription yield, need additional steps to remove linear RNA
Expression intensity
High transient expression intensity, followed by rapid decline
Comparable to mRNA expression with better persistence
Immunogenicity
High
Low
Applications
Applications requiring rapid expression of proteins
Applications requiring prolonged protein expression

Frequently asked questions

RNA-LNPs provide a non-viral approach for delivering RNA payloads and can support transient protein expression without requiring genomic integration of the therapeutic RNA sequence. LNPs can also co-deliver multiple RNA payloads, which can be useful for applications such as CRISPR gene editing. The optimal delivery system depends on the target cell, tissue, payload, dosing strategy, and therapeutic mechanism.

Yes. uBriGene can provide commercially available lipids for RNA-LNP formulation development and manufacturing and can also work with client-supplied custom lipids. The team can support formulation process development and technology transfer for client-specific RNA-LNP formulations.

A typical RNA-LNP formulation contains an ionizable lipid, phospholipid, cholesterol, and PEGylated lipid. The identity and ratio of each lipid, along with formulation conditions, can significantly affect particle characteristics, stability, biodistribution, and RNA delivery performance.

Key critical process parameters include lipid identity and ratios, RNA concentration, mixing conditions and flow rate, solvent conditions, tangential flow filtration (TFF) parameters, sterile filtration, and fill/finish conditions. Controlling these variables helps optimize RNA-LNP quality, consistency, stability, and process performance.

uBriGene supports RNA-LNP characterization including particle size and distribution by dynamic light scattering (DLS), RNA concentration and encapsulation efficiency using LC-UV and fluorescence-based methods, surface charge/zeta potential by electrophoretic light scattering (ELS), and lipid analysis using LC-MS. Process-related impurities such as template DNA, genomic DNA, lipids, and dsRNA can be assessed using techniques including capillary electrophoresis (CE), LC-MS, LC-UV, and LIF. Safety testing can include bioburden and endotoxin testing, with the final analytical panel tailored to the RNA modality and development stage.

RNA manufacturing typically involves a multi-enzyme in vitro transcription (IVT) process, and yield and quality can be affected by DNA template quality and purity, template design including the promoter, 5′ and 3′ UTRs and poly(A) tail, ORF characteristics such as hairpins or repetitive sequences, RNA transcript length, modified nucleotides, RNA polymerase, capping strategy, reaction conditions, RNase levels, downstream purification, and final product storage conditions. These parameters may require optimization according to the RNA sequence, manufacturing process, and intended application.

uBriGene reports achieving up to approximately 94% circRNA purity in process-development studies. Actual purity depends on the RNA sequence, circularization efficiency, purification conditions, and analytical methodology.

uBriGene produces circRNA using the PIE (permuted intron-exon) circularization method following in vitro transcription (IVT). Downstream purification is used to remove linear RNA and other process-related impurities. The purification strategy can be optimized according to the circRNA sequence and process requirements.

uBriGene's saRNA process development has achieved approximately 80–90% full-length RNA integrity, depending on the sequence. Because saRNA molecules are substantially larger than conventional mRNA, sequence design, IVT conditions, purification, and handling can affect full-length integrity.

uBriGene uses proprietary microfluidic mixing technology to combine the RNA-containing aqueous phase with lipid components in ethanol. The resulting RNA-LNPs are processed using tangential flow filtration for buffer exchange and concentration, followed by sterile filtration and, where required, aseptic fill/finish.

Self-amplifying RNA (saRNA) is an RNA modality engineered to encode both a therapeutic or antigen-encoding sequence and the machinery required for intracellular RNA amplification. This amplification can potentially support protein expression from a lower initial RNA dose, although performance depends on sequence design, target cells, delivery system, and application.

Key challenges in circRNA manufacturing include achieving efficient circularization, controlling reaction conditions, and removing residual linear RNA from the circularized product. uBriGene produces circRNA using the PIE (permuted intron-exon) circularization method following in vitro transcription, followed by downstream purification to remove linear RNA and other process-related impurities. The company reports achieving circRNA purity above 90% under its process conditions, with actual performance depending on sequence and process conditions.

Different RNA modalities can require different formulation and process conditions because RNA size, structure, concentration, and other molecular characteristics can affect encapsulation and particle properties. uBriGene evaluates formulation and process parameters according to the RNA payload to optimize encapsulation, particle quality, stability, and delivery performance.

uBriGene provides custom RNA production for mRNA, circRNA, self-amplifying RNA (saRNA), and sgRNA. Services can range from preclinical RNA production to GMP RNA and RNA-LNP manufacturing, with support that can include template construction, RNA synthesis, purification, LNP formulation, analytical testing, and fill/finish.

For the listed preclinical RNA production services, uBriGene indicates a typical turnaround time of approximately two weeks. Actual timing depends on the RNA modality, sequence, quantity, purification requirements, and project scope. GMP projects generally require additional development, testing, and release activities.

uBriGene supports custom RNA production from milligram to gram quantities for preclinical applications and provides GMP RNA and RNA-LNP manufacturing for clinical development. Manufacturing scale and final quantity are determined by the RNA modality, sequence, formulation, and project requirements.

Yes. uBriGene provides RNA production services ranging from preclinical research materials to GMP RNA and RNA-LNP manufacturing. An appropriate development and technology-transfer strategy can be established to transition a selected RNA construct and formulation toward GMP production, based on project requirements.

Need RNA, RNA-LNP Production?

Tap into our mRNA, circRNA, and saRNA manufacturing and LNP formulation expertise, focus your time on discovery research!

Request a Quote